更正：在具有表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）中，蛋白激酶Cα（PKCα）是Akt-雷帕霉素复合物1（mTORC1）激活所必需的。
Correction: PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.
作者信息
Salama Mohamed F, Liu Mengling, Clarke Christopher J, Espaillat Mel Pilar, Haley John D, Jin Ting, Wang Daifeng, Obeid Lina M, Hannun Yusuf A
机构信息
Department of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.
Stony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY, 11794, USA.
出版信息
Oncogene. 2019 Nov;38(48):7366. doi: 10.1038/s41388-019-1019-8.
PMID:31576014
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
摘要
本文的一个修订版本已发表，可通过本文顶部的链接获取。
相似文献
1
Correction: PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.更正：在具有表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）中，蛋白激酶Cα（PKCα）是Akt-雷帕霉素复合物1（mTORC1）激活所必需的。
Oncogene. 2019 Nov;38(48):7366. doi: 10.1038/s41388-019-1019-8.
2
Correction: VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.更正：多功能蛋白聚糖V1通过激活表皮生长因子受体-磷脂酰肌醇-3激酶-蛋白激酶B通路促进肝细胞癌的增殖和转移。
Oncogene. 2020 Feb;39(6):1388. doi: 10.1038/s41388-019-1095-9.
3
Author Correction: Achyranthes bidentata polysaccharide can safely prevent NSCLC metastasis via targeting EGFR and EMT.
Signal Transduct Target Ther. 2020 Oct 13;5(1):238. doi: 10.1038/s41392-020-00322-4.
4
Author Correction: Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK.作者更正：前列腺癌细胞对塞帕替尼（YM155）的早期细胞反应涉及AMPK对mTORC1的抑制。
Sci Rep. 2019 Oct 10;9(1):14826. doi: 10.1038/s41598-019-51007-0.
5
Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.作者更正：用FS-108靶向热休克蛋白90可克服表皮生长因子受体（EGFR）突变的非小细胞肺癌细胞中的吉非替尼耐药性。
Acta Pharmacol Sin. 2020 May;41(5):731-732. doi: 10.1038/s41401-019-0341-6.
6
Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.长链非编码RNA BC087858通过激活PI3K/AKT和MEK/ERK信号通路以及上皮-间质转化，诱导非小细胞肺癌产生非T790M突变的获得性EGFR-TKIs耐药。
Oncotarget. 2016 Aug 2;7(31):49948-49960. doi: 10.18632/oncotarget.10521.
7
Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer.非小细胞肺癌中 EGFR 和 KRAS 突变与 p-AKT、DR5 和 DcR1 表达的关系。
Neoplasma. 2017;64(2):182-191. doi: 10.4149/neo_2017_203.
8
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.P7170，一种新型的mTORC1/mTORC2和激活素受体样激酶1（ALK1）抑制剂，可抑制非小细胞肺癌的生长。
Mol Cancer. 2014 Dec 2;13:259. doi: 10.1186/1476-4598-13-259.
9
Author Correction: Isogambogenic acid induces apoptosis-independent autophagic cell death in human non-small-cell lung carcinoma cells.作者更正：异甘草酸诱导人非小细胞肺癌细胞发生非凋亡性自噬性细胞死亡。
Sci Rep. 2020 Apr 20;10(1):6895. doi: 10.1038/s41598-020-62992-y.
10
Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.表皮生长因子受体/ Akt 下游激酶驱动通路在人肺癌中的作用模式。
Hum Pathol. 2011 Feb;42(2):214-26. doi: 10.1016/j.humpath.2010.05.025. Epub 2010 Oct 30.
Zotero 插件